_________
false
÷îäãò áò"î
2
380
KAMADA LTD
Corporation no:
511524605
10991
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
25/08/2017
www.isa.gov.il
www.tase.co.il
Reference:
2017-02-074161
Time of broadcast:
14:04
14:03:34
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection
FDA_approval_for_KEDRAB_against_Rabies_infection_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
TASE
Date of revision of form structure:
09/08/2017
Address:
Holtzman 2
4081
,
Rehovot
7670402
ISRAEL
,
Tel:
08-9406472
,
Fax:
08-9406473
E-mail address:
liorf@kamada.com
Company site:
www.kamada.com
Previous names of reporting entity:
Name of the Signatory:
Fhima Lior
Position of Signatory in the reporting corporation:
Director of Finance
Name of Employer Company:
Address:
Sapir
7
,
Ness Ziona
7403630
Telephone:
08-9913168
Facsimile:
08-9912083
E-mail:
liorf@kamada.com
2